急性髓系白血病、骨髓增生异常肿瘤和慢性髓单细胞白血病患者骨髓CD8+ T细胞TCR库的比较分析

IF 3.7 3区医学 Q2 IMMUNOLOGY

European Journal of Immunology Pub Date : 2025-06-11 DOI:10.1002/eji.202551796

Kyriaki Katsiki, Athanasios Tasis, Anastasia Filia, Ioannis Kotsianidis, Ioannis Mitroulis

{"title":"急性髓系白血病、骨髓增生异常肿瘤和慢性髓单细胞白血病患者骨髓CD8+ T细胞TCR库的比较分析","authors":"Kyriaki Katsiki, Athanasios Tasis, Anastasia Filia, Ioannis Kotsianidis, Ioannis Mitroulis","doi":"10.1002/eji.202551796","DOIUrl":null,"url":null,"abstract":"<p>Bone marrow CD8<sup>+</sup> T cells from patients with MDS and CMML show decreased TCR diversity compared to AML. Treatment with the hypomethylating agent azacitidine in MDS and CMML alters TCR repertoire of CD8<sup>+</sup> T cells without affecting TCR diversity.\n\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":165,"journal":{"name":"European Journal of Immunology","volume":"55 6","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eji.202551796","citationCount":"0","resultStr":"{\"title\":\"Comparative Analysis of the TCR Repertoire in Bone Marrow CD8+ T Cells From Patients With Acute Myeloid Leukemia, Myelodysplastic Neoplasms, and Chronic Myelomonocytic Leukemia\",\"authors\":\"Kyriaki Katsiki, Athanasios Tasis, Anastasia Filia, Ioannis Kotsianidis, Ioannis Mitroulis\",\"doi\":\"10.1002/eji.202551796\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Bone marrow CD8<sup>+</sup> T cells from patients with MDS and CMML show decreased TCR diversity compared to AML. Treatment with the hypomethylating agent azacitidine in MDS and CMML alters TCR repertoire of CD8<sup>+</sup> T cells without affecting TCR diversity.\\n\\n <figure>\\n <div><picture>\\n <source></source></picture><p></p>\\n </div>\\n </figure></p>\",\"PeriodicalId\":165,\"journal\":{\"name\":\"European Journal of Immunology\",\"volume\":\"55 6\",\"pages\":\"\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-06-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eji.202551796\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/eji.202551796\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Immunology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/eji.202551796","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

与AML相比，MDS和CMML患者的骨髓CD8+ T细胞的TCR多样性降低。用低甲基化药物阿扎胞苷治疗MDS和CMML可改变CD8+ T细胞的TCR库，但不影响TCR多样性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Comparative Analysis of the TCR Repertoire in Bone Marrow CD8+ T Cells From Patients With Acute Myeloid Leukemia, Myelodysplastic Neoplasms, and Chronic Myelomonocytic Leukemia

查看原文本刊更多论文

Comparative Analysis of the TCR Repertoire in Bone Marrow CD8+ T Cells From Patients With Acute Myeloid Leukemia, Myelodysplastic Neoplasms, and Chronic Myelomonocytic Leukemia

Bone marrow CD8⁺ T cells from patients with MDS and CMML show decreased TCR diversity compared to AML. Treatment with the hypomethylating agent azacitidine in MDS and CMML alters TCR repertoire of CD8⁺ T cells without affecting TCR diversity.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European Journal of Immunology 医学-免疫学

CiteScore

8.30

自引率

3.70%

发文量

224

审稿时长

2 months

期刊介绍： The European Journal of Immunology (EJI) is an official journal of EFIS. Established in 1971, EJI continues to serve the needs of the global immunology community covering basic, translational and clinical research, ranging from adaptive and innate immunity through to vaccines and immunotherapy, cancer, autoimmunity, allergy and more. Mechanistic insights and thought-provoking immunological findings are of interest, as are studies using the latest omics technologies. We offer fast track review for competitive situations, including recently scooped papers, format free submission, transparent and fair peer review and more as detailed in our policies.